Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Optimizing buprenorphine training during undergraduate medical education: Medical student feedback and attitudes.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 9208821 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0391 (Electronic) Linking ISSN: 10550496 NLM ISO Abbreviation: Am J Addict Subsets: MEDLINE
    • Publication Information:
      Publication: Oxford : Wiley-Blackwell
      Original Publication: Washington, DC : American Psychiatric Press, c1992-
    • Subject Terms:
      Students, Medical* ; Education, Medical, Undergraduate* ; Buprenorphine*/therapeutic use ; Opioid-Related Disorders*; Humans ; Feedback ; Attitude ; Opiate Substitution Treatment ; Analgesics, Opioid/therapeutic use
    • Abstract:
      Background and Objectives: Strong evidence supports efficacy of medications for opioid use disorder (MOUD), but stringent prescribing policies impair access. Many physicians report discomfort prescribing MOUD due to inadequate knowledge. Most medical students believe MOUD training should occur during undergraduate medical education (UME). As legislation surrounding buprenorphine prescribing shifts, it is timely to consider how best to incorporate MOUD training into UME.
      Methods: At the start of 3rd year, all students (n = 290) received a survey regarding experiences working with people with OUDs, and beliefs and knowledge regarding harm reduction and treatment. During orientation, students completed an 8-h online MOUD training. Afterwards, students completed another survey, including questions about training perceptions.
      Results: One-third of students (32.8%) completed MOUD training and both surveys. Before training, 60.0% had not heard of the waiver, but 82.1% endorsed interest in prescribing buprenorphine. Despite mixed feelings about training content and delivery, 79.1% believed future classes should receive it. Most thought it should be integrated longitudinally throughout the curriculum rather than as separate online training.
      Conclusion and Scientific Significance: Medical students want more MOUD education throughout their training; however, the 8-h online training may be less-than-optimal. As this training is no longer required to prescribe buprenorphine, there is an opportunity to modify the content presented. There is an urgent need for physicians with the knowledge and willingness to treat patients with OUD. Introducing integrated training about MOUD should help future physicians feel confident in their knowledge to treat patients and comfortable applying for the waiver.
      (© 2023 The American Academy of Addiction Psychiatry (AAAP).)
    • References:
      Addict Sci Clin Pract. 2018 Aug 6;13(1):18. (PMID: 30078375)
      AEM Educ Train. 2018 Mar 30;2(2):174-177. (PMID: 30051085)
      Expert Opin Pharmacother. 2009 Aug;10(11):1727-40. (PMID: 19538000)
      J Prim Care Community Health. 2022 Jan-Dec;13:21501319221112272. (PMID: 35822763)
      Harm Reduct J. 2022 Jul 2;19(1):70. (PMID: 35780103)
      Subst Abus. 2019;40(2):240-246. (PMID: 30767715)
      J Addict Dis. 2006;25(4):91-103. (PMID: 17088229)
      Med Educ Online. 2021 Dec;26(1):1847755. (PMID: 33222656)
      Acad Med. 2016 Oct;91(10):1348-1351. (PMID: 27532868)
      Acad Psychiatry. 2016 Jun;40(3):454-60. (PMID: 25749922)
      Drug Alcohol Depend. 2013 Sep 1;132(1-2):383-6. (PMID: 23453260)
      N Engl J Med. 2019 Jan 3;380(1):3-5. (PMID: 30428274)
      J Gen Intern Med. 2018 Jun;33(6):797-798. (PMID: 29556799)
      J Addict Dis. 2020 Jul-Sep;38(3):380-383. (PMID: 32449488)
      J Addict Med. 2021 May-Jun 01;15(3):219-225. (PMID: 33079729)
      Subst Abus. 2021;42(2):236-243. (PMID: 33821773)
      JAMA Psychiatry. 2021 Sep 1;78(9):979-993. (PMID: 34076676)
      JAMA. 2016 Jul 19;316(3):282-90. (PMID: 27434441)
      JAMA Intern Med. 2018 Jun 1;178(6):764-773. (PMID: 29799968)
      Subst Abus. 2020;41(4):463-467. (PMID: 32031914)
      N C Med J. 2019 May-Jun;80(3):191-192. (PMID: 31072954)
      Lancet. 2018 Jan 27;391(10118):309-318. (PMID: 29150198)
      N Engl J Med. 2022 Oct 13;387(15):1341-1344. (PMID: 36129991)
      Drug Alcohol Depend. 2019 Nov 1;204:107527. (PMID: 31525570)
      Addict Behav. 2022 Mar;126:107172. (PMID: 34774365)
      Acad Med. 2022 Feb 1;97(2):182-187. (PMID: 33538477)
      Subst Abus. 2021;42(4):692-698. (PMID: 33166242)
      J Pharmacol Exp Ther. 2019 Nov;371(2):500-506. (PMID: 31320493)
      J Med Educ Curric Dev. 2020 Jun 02;7:2382120520923994. (PMID: 32537516)
      BMC Fam Pract. 2019 Nov 15;20(1):157. (PMID: 31729957)
      J Addict Dis. 2023 Apr-Jun;41(2):156-166. (PMID: 35470767)
      Subst Abus. 2022;43(1):309-318. (PMID: 34214397)
      Health Serv Res. 2019 Apr;54(2):390-398. (PMID: 30665272)
      Subst Abus. 2020;41(1):29-34. (PMID: 31211657)
      J Am Board Fam Med. 2021 Nov-Dec;34(6):1212-1215. (PMID: 34772776)
      Am J Prev Med. 2018 Jun;54(6 Suppl 3):S230-S242. (PMID: 29779547)
      Subst Abus. 2020;41(2):245-251. (PMID: 31170030)
    • Grant Information:
      F30 DA052118 United States DA NIDA NIH HHS
    • Accession Number:
      40D3SCR4GZ (Buprenorphine)
      0 (Analgesics, Opioid)
    • Publication Date:
      Date Created: 20230228 Date Completed: 20230703 Latest Revision: 20240702
    • Publication Date:
      20250114
    • Accession Number:
      PMC10313763
    • Accession Number:
      10.1111/ajad.13395
    • Accession Number:
      36850044